Skip to main content
Premium Trial:

Request an Annual Quote

RXi Posts Flat Q3 Net Loss

Premium

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its third-quarter financial results, posting a net loss essentially flat with last year as expenses held steady.

For the three-month period ended Sept. 30, RXi's net loss was $2.2 million, or $.17 a share, compared with $2.1 million, or $.30 a share, the year before.

Research and development spending in the quarter was $1.5 million, up slightly from expenses of $1.2 million a year ago. General and administrative costs, meanwhile, dipped to $2.5 million from $2.6 million.

At the end of the third quarter, RXi had cash, cash equivalents, and short-term investments totaling $10.1 million.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.